Latest Headlines

Latest Headlines

Growing popularity of virtual biotechs promises boon to outsourcers

The recent news that tiny FerroKin BioSciences earned a big buyout deal with Shire has helped spotlight the growing  virtual biotech model.

Biogen Idec scores lung disease drug in $562.5M buyout of Stromedix

Biogen Idec ($BIIB) has scooped up a biotech very close to home. The Weston, MA-based biotech power has bought nearby Stromedix, whose lead fibrosis drug STX-100 was licensed from Biogen. The deal

Stromedix closing in on new venture round

Stromedix CEO Michael Gilman appears to be making headway in his quest to round up an additional $15 million in venture funds for his virtual biotech. Quoting documents filed with the feds, Mass High

Stromedix's STX-100 falls behind schedule

When Cambridge, MA-based Stromedix raised $25 million in 2008, CEO Michael Gilman said he hoped to have the company's lead drug, STX-100, well into Phase II trials by mid-2010. The drug, which was

Stromedix gets $25M for mAb work

Cambridge, MA-based Stromedix has landed $25 million in a Series B round of venture capital. The company's lead drug is STX-100, a humanized monoclonal antibody which Stromedix is developing for